Search alternatives:
significantly improved » significantly increased (Expand Search)
significantly longer » significantly lower (Expand Search), significantly larger (Expand Search), significantly higher (Expand Search)
improved decrease » improved urease (Expand Search), marked decrease (Expand Search)
longer decrease » larger decrease (Expand Search), linear decrease (Expand Search), largest decrease (Expand Search)
Showing 61 - 80 results of 5,857 for search '(( significantly longer decrease ) OR ( significantly improved decrease ))*', query time: 0.31s Refine Results
  1. 61
    The comparison of GCF visfatin level before and three months after NSPT among cases with periodontitis and T2DM.

    The comparison of GCF visfatin level before and three months after NSPT among cases with periodontitis and T2DM. by Zahra Tajik (20752452)

    Published 2025
    Subjects:
    Save to List
    Saved in:
  2. 62
    List of excluded studies.

    List of excluded studies. by Zahra Tajik (20752452)

    Published 2025
    Subjects:
    Save to List
    Saved in:
  3. 63
    Image 3_Endolysin significantly improves symptoms with atopic dermatitis: bridging the gap from research to clinical practice.jpeg

    Image 3_Endolysin significantly improves symptoms with atopic dermatitis: bridging the gap from research to clinical practice.jpeg by Ling Kui (6108440)

    Published 2025
    “…Compared to baseline, EASI, SCORAD, IGA, VAS, and DLQI scores demonstrated significant decreases at both Day 7 and Day 14 (all P < 0.05). …”
    Save to List
    Saved in:
  4. 64
    Image 4_Endolysin significantly improves symptoms with atopic dermatitis: bridging the gap from research to clinical practice.jpeg

    Image 4_Endolysin significantly improves symptoms with atopic dermatitis: bridging the gap from research to clinical practice.jpeg by Ling Kui (6108440)

    Published 2025
    “…Compared to baseline, EASI, SCORAD, IGA, VAS, and DLQI scores demonstrated significant decreases at both Day 7 and Day 14 (all P < 0.05). …”
    Save to List
    Saved in:
  5. 65
    Image 2_Endolysin significantly improves symptoms with atopic dermatitis: bridging the gap from research to clinical practice.jpeg

    Image 2_Endolysin significantly improves symptoms with atopic dermatitis: bridging the gap from research to clinical practice.jpeg by Ling Kui (6108440)

    Published 2025
    “…Compared to baseline, EASI, SCORAD, IGA, VAS, and DLQI scores demonstrated significant decreases at both Day 7 and Day 14 (all P < 0.05). …”
    Save to List
    Saved in:
  6. 66
    Table 2_Endolysin significantly improves symptoms with atopic dermatitis: bridging the gap from research to clinical practice.docx

    Table 2_Endolysin significantly improves symptoms with atopic dermatitis: bridging the gap from research to clinical practice.docx by Ling Kui (6108440)

    Published 2025
    “…Compared to baseline, EASI, SCORAD, IGA, VAS, and DLQI scores demonstrated significant decreases at both Day 7 and Day 14 (all P < 0.05). …”
    Save to List
    Saved in:
  7. 67
    Table 3_Endolysin significantly improves symptoms with atopic dermatitis: bridging the gap from research to clinical practice.xlsx

    Table 3_Endolysin significantly improves symptoms with atopic dermatitis: bridging the gap from research to clinical practice.xlsx by Ling Kui (6108440)

    Published 2025
    “…Compared to baseline, EASI, SCORAD, IGA, VAS, and DLQI scores demonstrated significant decreases at both Day 7 and Day 14 (all P < 0.05). …”
    Save to List
    Saved in:
  8. 68
    Table 1_Endolysin significantly improves symptoms with atopic dermatitis: bridging the gap from research to clinical practice.xlsx

    Table 1_Endolysin significantly improves symptoms with atopic dermatitis: bridging the gap from research to clinical practice.xlsx by Ling Kui (6108440)

    Published 2025
    “…Compared to baseline, EASI, SCORAD, IGA, VAS, and DLQI scores demonstrated significant decreases at both Day 7 and Day 14 (all P < 0.05). …”
    Save to List
    Saved in:
  9. 69
    Image 1_Endolysin significantly improves symptoms with atopic dermatitis: bridging the gap from research to clinical practice.jpeg

    Image 1_Endolysin significantly improves symptoms with atopic dermatitis: bridging the gap from research to clinical practice.jpeg by Ling Kui (6108440)

    Published 2025
    “…Compared to baseline, EASI, SCORAD, IGA, VAS, and DLQI scores demonstrated significant decreases at both Day 7 and Day 14 (all P < 0.05). …”
    Save to List
    Saved in:
  10. 70
    Table 4_Endolysin significantly improves symptoms with atopic dermatitis: bridging the gap from research to clinical practice.xlsx

    Table 4_Endolysin significantly improves symptoms with atopic dermatitis: bridging the gap from research to clinical practice.xlsx by Ling Kui (6108440)

    Published 2025
    “…Compared to baseline, EASI, SCORAD, IGA, VAS, and DLQI scores demonstrated significant decreases at both Day 7 and Day 14 (all P < 0.05). …”
    Save to List
    Saved in:
  11. 71
    Significant associations in GWAS.

    Significant associations in GWAS. by Dai Nogimura (21445649)

    Published 2025
    “…<div><p>Decreased nitric oxide (NO) production from the vascular endothelium is a major factor for vascular aging. …”
    Save to List
    Saved in:
  12. 72
    Demonstration of decreased Aβ accumulation by DA-9601 treatment.

    Demonstration of decreased Aβ accumulation by DA-9601 treatment. by Mijung Lee (397790)

    Published 2024
    Save to List
    Saved in:
  13. 73
    Prisma flow diagram of study selection.

    Prisma flow diagram of study selection. by Hattapark Dejakaisaya (22238613)

    Published 2025
    Subjects:
    Save to List
    Saved in:
  14. 74
    Sensitivity and subgroup analysis between higher TV watching time and cognitive scores.

    Sensitivity and subgroup analysis between higher TV watching time and cognitive scores. by Hattapark Dejakaisaya (22238613)

    Published 2025
    Subjects:
    Save to List
    Saved in:
  15. 75
    Sensitivity and subgroup analysis of conventional meta-analysis of TV watching time and risk of cognitive impairment.

    Sensitivity and subgroup analysis of conventional meta-analysis of TV watching time and risk of cognitive impairment. by Hattapark Dejakaisaya (22238613)

    Published 2025
    Subjects:
    Save to List
    Saved in:
  16. 76
    The main characteristics of the 35 studies included in the systematic review categorized by their study designs.

    The main characteristics of the 35 studies included in the systematic review categorized by their study designs. by Hattapark Dejakaisaya (22238613)

    Published 2025
    Subjects:
    Save to List
    Saved in:
  17. 77
    Schematic diagram of the molecular mechanism by which TRIM37 improves MS by stabilizing PEX5 through monoubiquitination.

    Schematic diagram of the molecular mechanism by which TRIM37 improves MS by stabilizing PEX5 through monoubiquitination. by Lai Jiang (2401513)

    Published 2025
    Subjects:
    Save to List
    Saved in:
  18. 78
    DataSheet1_Significant nocturnal wakefulness after sleep onset in metabolic dysfunction–associated steatotic liver disease.PDF

    DataSheet1_Significant nocturnal wakefulness after sleep onset in metabolic dysfunction–associated steatotic liver disease.PDF by Sofia Schaeffer (20379954)

    Published 2024
    “…HC 8.5 vs. 5.5, p = 0.0036), longer wakefulness after sleep onset (MASLD vs. HC 45.4 min vs. 21.3 min, p = 0.0004), and decreased sleep efficiency (MASLD vs. …”
    Save to List
    Saved in:
  19. 79
    DataSheet3_Significant nocturnal wakefulness after sleep onset in metabolic dysfunction–associated steatotic liver disease.PDF

    DataSheet3_Significant nocturnal wakefulness after sleep onset in metabolic dysfunction–associated steatotic liver disease.PDF by Sofia Schaeffer (20379954)

    Published 2024
    “…HC 8.5 vs. 5.5, p = 0.0036), longer wakefulness after sleep onset (MASLD vs. HC 45.4 min vs. 21.3 min, p = 0.0004), and decreased sleep efficiency (MASLD vs. …”
    Save to List
    Saved in:
  20. 80
    DataSheet2_Significant nocturnal wakefulness after sleep onset in metabolic dysfunction–associated steatotic liver disease.PDF

    DataSheet2_Significant nocturnal wakefulness after sleep onset in metabolic dysfunction–associated steatotic liver disease.PDF by Sofia Schaeffer (20379954)

    Published 2024
    “…HC 8.5 vs. 5.5, p = 0.0036), longer wakefulness after sleep onset (MASLD vs. HC 45.4 min vs. 21.3 min, p = 0.0004), and decreased sleep efficiency (MASLD vs. …”
    Save to List
    Saved in:

Search Tools: